Download image

VM Cariprazine

Visual representation of the interaction
Mode of action
Cariprazine
Transporter zone
No interaction
Enzyme zone
No interaction
Receptor zone
Important for clinical effects
Important for clinical effects
Contributes to other effects
Important for clinical effects
Ion channel zone
No interaction

NbN-2 cariprazine

Mode of action
receptor partial agonist (D2, 5-HT1A), receptor antagonist (5-HT2B)
Pharmacological target
dopamine, serotonin
Date published
10.02.2017

Cariprazine

For more detailed explanation of the principles of the VM Library
For more detailed explanation of the Neuroscience based Nomenclature

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

References
  1. Girgis RR, Slifstein M, D'Souza D, et al. (2016) Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl) 233: 3503-3512.
  2. Kiss B, Horvath A, Nemethy Z, et al. (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333: 328-340.
  3. Lao KS, He Y, Wong IC, et al. (2016) Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. CNS Drugs.
  4. NbN-2 www.nbn2.com
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country